Cargando…

Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities

In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TI...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahin, Amira, Elsawaf, Amani, Ramadan, Shahira, Shaker, Olfat, Amin, Mona, Taha, Mohamed
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1775032/
https://www.ncbi.nlm.nih.gov/pubmed/17392585
http://dx.doi.org/10.1155/MI/2006/38458
_version_ 1782131730237358080
author Shahin, Amira
Elsawaf, Amani
Ramadan, Shahira
Shaker, Olfat
Amin, Mona
Taha, Mohamed
author_facet Shahin, Amira
Elsawaf, Amani
Ramadan, Shahira
Shaker, Olfat
Amin, Mona
Taha, Mohamed
author_sort Shahin, Amira
collection PubMed
description In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TIMP-2 concentration measurement using ELISA technique were performed in all patients and in 25 normal controls. The mean serum levels of TIMP-2 in patients was higher than in controls (P = .005). The mean CT score of dSSc patients with elevated TIMP-2 levels was significantly higher than dSSc patients with normal levels (P = .013). Four patients out of five with elevated TIMP-2 levels showed diastolic dysfunction (80%), compared to 2 out of 15 lSSc patients with normal levels (13.3%), with P = .014. Our research, though involving a small group of patients, points to the probable role of TIMP-2 in the development of pulmonary lesions in dSSc patients and cardiac lesions in lSSc patients with duration equal to or more than 2 years.
format Text
id pubmed-1775032
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-17750322007-02-20 Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities Shahin, Amira Elsawaf, Amani Ramadan, Shahira Shaker, Olfat Amin, Mona Taha, Mohamed Mediators Inflamm Research Communication In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TIMP-2 concentration measurement using ELISA technique were performed in all patients and in 25 normal controls. The mean serum levels of TIMP-2 in patients was higher than in controls (P = .005). The mean CT score of dSSc patients with elevated TIMP-2 levels was significantly higher than dSSc patients with normal levels (P = .013). Four patients out of five with elevated TIMP-2 levels showed diastolic dysfunction (80%), compared to 2 out of 15 lSSc patients with normal levels (13.3%), with P = .014. Our research, though involving a small group of patients, points to the probable role of TIMP-2 in the development of pulmonary lesions in dSSc patients and cardiac lesions in lSSc patients with duration equal to or more than 2 years. Hindawi Publishing Corporation 2006 2006-12-20 /pmc/articles/PMC1775032/ /pubmed/17392585 http://dx.doi.org/10.1155/MI/2006/38458 Text en Copyright © 2006 Amira Shahin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Communication
Shahin, Amira
Elsawaf, Amani
Ramadan, Shahira
Shaker, Olfat
Amin, Mona
Taha, Mohamed
Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
title Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
title_full Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
title_fullStr Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
title_full_unstemmed Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
title_short Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities
title_sort serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities
topic Research Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1775032/
https://www.ncbi.nlm.nih.gov/pubmed/17392585
http://dx.doi.org/10.1155/MI/2006/38458
work_keys_str_mv AT shahinamira serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities
AT elsawafamani serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities
AT ramadanshahira serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities
AT shakerolfat serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities
AT aminmona serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities
AT tahamohamed serumlevelsoftissueinhibitorsofmetalloproteinase2inpatientswithsystemicsclerosiswithdurationmorethan2yearscorrelationwithcardiacandpulmonaryabnormalities